期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

左西孟旦的研究新进展 被引量：66

下载PDF
导出
摘要 传统正性肌力药物通过增加细胞内环磷酸腺苷的含量和Ca2+浓度,长期使用,增加心肌顿抑和恶性心律失常的发生率。Ca2+敏感药-左西孟旦是一种新型的治疗心力衰竭的药物,通过增加肌丝对Ca2+的敏感性而发挥作用,降低心脏的能量需求,故可以避免传统正性肌力药物导致的心律失常、心肌细胞损伤甚至死亡,此外还具有抗炎、抗氧化、抗心肌细胞凋亡作用。本文就左西孟旦的作用机制、对心血管系统的影响及在临床应用中新进展、前景等做一综述。
作者 杜贺 史承勇 陈少萍
机构地区 中国人民解放军第二军医大学附属长海医院心内科 中国人民解放军
出处 《中国循环杂志》 CSCD 北大核心 2014年第7期555-557,共3页 Chinese Circulation Journal
关键词 左西孟旦 心力衰竭
分类号 R541 [医药卫生—心血管疾病]
  • 相关文献

参考文献28

  • 1张健,张宇辉.我国迫切需要开展前瞻性心力衰竭注册研究[J].中国循环杂志,2013,28(2):158-158. 被引量：5
  • 2杨跃进.心力衰竭的进展(12)心力衰竭药物治疗的研究进展(续7)[J].中国循环杂志,2006,21(6):407-411. 被引量：12
  • 3Burger AJ, Horton DP, LeJemtel T, et al. Effect of nesiritide (B-type natriuretic peptide) and dohutamine on ventricular arrhythmias in the treatment of patients with acuteiy decompensated congestive heart failure: the PRECEDENT study. Am Heart J, 2002, 144:1102-1108.
  • 4Rognoni A, Lupi A, Lazzero M, et al. Levosimendan: from basic science to clinical trials. Recent Pat Cardiovasc Drug Discov, 2011, 6: 9-15.
  • 5Antila S, Kivikko M, Lehtonen L, et al. Pharmacokinetics of levosimendan and its circulating metaholites in patients with heart failure after an extended continuous infusion of ]evosimendan. Br J Clin Pharmacol, 2004, 57: 412-415.
  • 6Szil e gyi S, Pollesello P, Levijoki J, et al. The effects of levosimendan and OR-1896 on isolated hearts, myncyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Euro J Pharmacol, 2004, 486: 67-74.
  • 7Rognoni A, Lupi A, Lazzero M, et al. Levosimendan: from basic science to clinical trials. Recent Pat Cardiovasc Drug Discov, 2011, 6:9-15.
  • 8Toiler WG, Stranz C. Levosimendan, a new inotropic and vasodilator agent. Anesthesiol, 2006, 104: 556-569.
  • 9Mebazaa A, Nieminen MS, Filippatos GS, et al. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on 13 -blockers in SURVIVE. Euro J Heart fail, 2009, 11 : 304-311.
  • 10Parissis JT, Andreadou I, Bistula V, et al. Novel biologic mechanisms of levosimendan and its effect on the failing heart. Expert Opin lnvestig Drugs, 2008, 17:1143-1150.

二级参考文献13

  • 1Dec GW. Acute decompensated heart failure: the shrinking role of inotropic therapy[J]. J Am Coll Cardiol, 2005, 46(1):65.
  • 2Endon M.Mechanisms of action of novel cardiotonic agents [J] .J Cardiovasc Pharmacol, 2002,40 (3) : 323.
  • 3Papp Z, Csapo K, Pollesello P, et al.Pharmacological mechanisms contributing to the clinical efficacy of levosimendan[J]. Cardiov Dse Drug Rev, 2005,23 ( 1 ) : 71.
  • 4Grossini E, Molinari C, Caimmi PP, et al.Levosimendan induces NO production through p38 MAPK, ERK and Akt in porcine coronary endothelial cells: role for mitochondrial K(ATP) charmel.[J] BrJPharmacol, 2009 , 156 (2):250.
  • 5Kivikko M, Antila S, Eha J, et al.Pharmacodynamics and Safety of a New Calcium Sensitizer, Levosimendan, and Its Metabolites during an Extendedlnfusion in Patients with Severe Heart Failure[J]. J Clin Pharmacol, 2002, 42 (1):43.
  • 6Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study) : a randomised double-blind trial[J]. Lancet, 2002,360 (9 328) : 196.
  • 7Moiseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN) [J]. Eur Heart J, 2002, 23 (18):1 422.
  • 8Cleland JG, Ghosh J, Freemantle N, et al.Clinical trials update and cumulative Meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure[J]. Eur J Heart Fail , 2004 , 6 ( 4 ) :501.
  • 9Packer M, Colueci WS, Fisher L, et al.Development of a comprehensive new end point for the evaluation of new treatments for acute decompensated heart failure:results with levosimendan in the REVIVE 1 study[J].J CardFail, 2003,9(5) :61.
  • 10Packer M.REVIVE-2.. Levosimendan improves five-day clinical status in acute HF[R].USA: American Heart Association Scientific Sessions, 2005.

共引文献42

同被引文献452

引证文献66

二级引证文献504

中国循环杂志
2014年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部